Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F12%3A10135327" target="_blank" >RIV/00669806:_____/12:10135327 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.nature.com/bmt/journal/v47/n5/pdf/bmt2011156a.pdf" target="_blank" >http://www.nature.com/bmt/journal/v47/n5/pdf/bmt2011156a.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/bmt.2011.156" target="_blank" >10.1038/bmt.2011.156</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT

Popis výsledku v původním jazyce

Oral cavity cooling (cryotherapy) provided during high-dose melphalan bolus or short-infusion administration contributes to local vasoconstriction, lower blood circulation, lower local cytotoxic drug exposure and significantly reduced oral mucositis (OM)incidence.1-3 OM is a significant posttransplant complication, and together with gut tissue damage and inflammation, caused by conditioning regimens, contributes to the development and pathogenesis of acute GVHD.4-6 The incidence of acute GVHD varies between 28 and 45% in the Flu/Mel-reduced intensity conditioning regimen comprising of fludarabine total dose 125-150mg/m2 and melphalan total dose 140-180mg/m2.1,7-9 We decided to analyze the impact of reduced OMincidence (reduced oral tissue damage) on acute GVHD, and analyzed 142 prospectively observed patients after Flu/Mel (fludarabine 30mg/m2 i.v. once daily for 4 days, melphalan 140mg/m2 i.v. one day before transplantation) allo-SCT performed at our institution from January 2005 to

Název v anglickém jazyce

Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT

Popis výsledku anglicky

Oral cavity cooling (cryotherapy) provided during high-dose melphalan bolus or short-infusion administration contributes to local vasoconstriction, lower blood circulation, lower local cytotoxic drug exposure and significantly reduced oral mucositis (OM)incidence.1-3 OM is a significant posttransplant complication, and together with gut tissue damage and inflammation, caused by conditioning regimens, contributes to the development and pathogenesis of acute GVHD.4-6 The incidence of acute GVHD varies between 28 and 45% in the Flu/Mel-reduced intensity conditioning regimen comprising of fludarabine total dose 125-150mg/m2 and melphalan total dose 140-180mg/m2.1,7-9 We decided to analyze the impact of reduced OMincidence (reduced oral tissue damage) on acute GVHD, and analyzed 142 prospectively observed patients after Flu/Mel (fludarabine 30mg/m2 i.v. once daily for 4 days, melphalan 140mg/m2 i.v. one day before transplantation) allo-SCT performed at our institution from January 2005 to

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bone Marrow Transplantation

ISSN

0268-3369

e-ISSN

—

Svazek periodika

47

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

3

Strana od-do

739-741

Kód UT WoS článku

000303923500021

EID výsledku v databázi Scopus

—